The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

BACKGROUND: Recently, a series of clinical trials showed that combination of anti-programmed cell death-1 (α-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (α-CTLA-4) could effectively eliminate tumor. However, in comparison with widely adopted mono-immune checkpoint inhibitors, chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kongju, Yi, Ming, Qin, Shuang, Chu, Qian, Zheng, Xinhua, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815037/
https://www.ncbi.nlm.nih.gov/pubmed/31673481
http://dx.doi.org/10.1186/s40164-019-0150-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815037/
https://www.ncbi.nlm.nih.gov/pubmed/31673481
http://dx.doi.org/10.1186/s40164-019-0150-0

Ejemplares similares